ArticleVeterinary pathology2026
Immunohistochemical expression of ΔNp63 versus pan-p63 in normal and neoplastic feline tissues.
Article in Veterinary pathology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
ΔNp63 is an isoform of p63 that plays an essential role in the development and growth of some epithelial tissues. In this study, we investigated the expression of ΔNp63 in normal and neoplastic tissues of cats and compared the results with the expression of pan-p63. Immunohistochemistry for ΔNp63 and pan-p63 was performed in normal tissues from 2 adult cats and in 10 cases each of 22 different types of feline neoplasms. In normal tissues, there was nuclear ΔNp63 immunolabeling in basal cells of stratified squamous, transitional, and pseudostratified columnar epithelia; basal cells of sebaceous glands; trophoblasts; and myoepithelial cells. Of the neoplasms, 10/10 apocrine ductal adenomas, 10/10 mammary ductal carcinomas, 10/10 pulmonary adenosquamous carcinomas, 10/10 squamous cell carcinomas, 10/10 trichoblastomas, and 10/10 urothelial carcinomas immunolabeled for ΔNp63. The ΔNp63 immunolabeling was diffuse in almost all neoplastic cells with squamous, basal, and urothelial origins. In the neoplasms with ductal differentiation, only the neoplastic suprabasal myoepithelial cells immunolabeled. Application of pan-p63 to the same set of neoplasms revealed positivity not only in the same neoplasms, but also in several unexpected tumor types (3/10 exocrine pancreatic carcinomas, 3/10 fibrosarcomas, 3/10 pulmonary adenocarcinomas, 2/10 lymphomas, 1/10 cholangiocarcinomas, 1/10 hemangiosarcomas, 1/10 mast cell tumors, and 1/10 meningiomas). Both ΔNp63 and pan-p63 antibodies demonstrated 100% diagnostic sensitivity and negative predictive value for diagnosing feline neoplasms with squamous, basal, and urothelial epithelia or myoepithelial cells. However, ΔNp63 showed higher diagnostic specificity (100% vs. 90.6%), positive predictive value (100% vs. 80%), and overall accuracy (100% vs. 93.1%) compared with pan-p63.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.